secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001213900-26-002344
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission
-------------------------------------------------------------------------------

- FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.
- BLA submission for Sonelokimab in HS on track for H2 2026; Investor Day set for Feb 23, 2026 to discuss FDA feedback and new data.
- FDA advised including VELA-2 results in BLA to inform safety profile, regardless of role in establishing effectiveness.
- Upcoming milestones: Phase 2 S-OLARIS (axSpA) Q1 2026; Phase 3 IZAR-1 (PsA) mid-2026; VELA-TEEN adolescent HS readout mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026002344/0001213900-26-002344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026002344/ea0272252-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer